Literature DB >> 7496972

Molecular basis for serological cross-reactivity between enteroviruses.

A Samuelson1, M Forsgren, B Johansson, B Wahren, M Sällberg.   

Abstract

The recognition sites for human antibodies which are cross-reactive between different types of enteroviruses were determined and characterized. Serum samples obtained from 58 patients with culture-confirmed enteroviral infections were analyzed in enzyme immunoassays against two sets of overlapping synthetic peptides covering residues 31 to 96 of poliovirus 1 VP1 (Mahoney strain) and residues 31 to 148 of coxsackievirus B1 VP1 (position based on alignment with poliovirus 1 VP1, Mahoney strain). A major antigenic region eliciting cross-reactive antibodies could be located to residues 37 to 51 of VP1. Furthermore, a single peptide covering residues 42 to 55 almost completely inhibited the binding of human antibodies to heat-inactivated enteroviruses, indicating that residues 42 to 55 of VP1 contain a major region eliciting cross-reactive antibodies. By using peptide analogs in which each residue within positions 42 to 55 of VP1 was sequentially substituted by Ala or Gly, we were able to determine the most essential residues for human antibody binding in 38 of the convalescent-phase patient serum samples. In a majority of the serum samples, the most essential residues for antibody binding were found to be Pro-42, Ala-43, Leu-44, Thr-45, Ala-46, Glu-48, Thr-49, and Gly-50. All of these residues are conserved, according to known enterovirus sequences, with the divergent echovirus 22 excepted. In conclusion, we could demonstrate that the essential residues for binding of cross-reactive antibodies are well conserved within the enterovirus family. These findings provide a molecular basis for the observed antibody cross-reactivity within the enterovirus group.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7496972      PMCID: PMC368258          DOI: 10.1128/cdli.1.3.336-341.1994

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  23 in total

1.  General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids.

Authors:  R A Houghten
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

2.  Antigenic structure of polioviruses of serotypes 1, 2 and 3.

Authors:  P D Minor; M Ferguson; D M Evans; J W Almond; J P Icenogle
Journal:  J Gen Virol       Date:  1986-07       Impact factor: 3.891

3.  The complete nucleotide sequence of coxsackievirus B4 and its comparison to other members of the Picornaviridae.

Authors:  O Jenkins; J D Booth; P D Minor; J W Almond
Journal:  J Gen Virol       Date:  1987-07       Impact factor: 3.891

4.  Three-dimensional structure of poliovirus at 2.9 A resolution.

Authors:  J M Hogle; M Chow; D J Filman
Journal:  Science       Date:  1985-09-27       Impact factor: 47.728

5.  Complete nucleotide sequence of the genome of coxsackievirus B1.

Authors:  N Iizuka; S Kuge; A Nomoto
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

6.  Three-dimensional structure of poliovirus serotype 1 neutralizing determinants.

Authors:  G S Page; A G Mosser; J M Hogle; D J Filman; R R Rueckert; M Chow
Journal:  J Virol       Date:  1988-05       Impact factor: 5.103

7.  Primary structure, gene organization and polypeptide expression of poliovirus RNA.

Authors:  N Kitamura; B L Semler; P G Rothberg; G R Larsen; C J Adler; A J Dorner; E A Emini; R Hanecak; J J Lee; S van der Werf; C W Anderson; E Wimmer
Journal:  Nature       Date:  1981-06-18       Impact factor: 49.962

8.  N-AgIB of poliovirus type 1: a discontinuous epitope formed by two loops of VP1 comprising residues 96-104 and 141-152.

Authors:  K Wiegers; H Uhlig; R Dernick
Journal:  Virology       Date:  1989-06       Impact factor: 3.616

9.  Epidemiological features of type 22 echovirus infection.

Authors:  A Ehrnst; M Eriksson
Journal:  Scand J Infect Dis       Date:  1993

10.  Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome.

Authors:  A Nomoto; T Omata; H Toyoda; S Kuge; H Horie; Y Kataoka; Y Genba; Y Nakano; N Imura
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  20 in total

1.  Quantitative PCR-enhanced immunoassay for measurement of enteroviral immunoglobulin M antibody and diagnosis of aseptic meningitis.

Authors:  Amal Elfaitouri; Nahla Mohamed; Jan Fohlman; Robert Aspholm; Gun Frisk; Göran Friman; Lars Magnius; Jonas Blomberg
Journal:  Clin Diagn Lab Immunol       Date:  2005-02

2.  Characterization of the recognition site and diagnostic potential of an enterovirus group-reactive monoclonal antibody.

Authors:  A Samuelson; M Forsgren; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

3.  Sequence analysis of echoviruses in a major antigenic region eliciting enteroviral cross-reactive antibodies.

Authors:  A Samuelson; B Johansson; M Forsgren
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

4.  Irregular poliovirus vaccination correlates to pulmonary edema of hand, foot, and mouth disease.

Authors:  Chaoyang Deng; Chunfu Yang; Junfeng Wan; Liye Zhu; Qibin Leng
Journal:  Clin Vaccine Immunol       Date:  2011-07-13

Review 5.  Molecular typing of enteroviruses: current status and future requirements. The European Union Concerted Action on Virus Meningitis and Encephalitis.

Authors:  P Muir; U Kämmerer; K Korn; M N Mulders; T Pöyry; B Weissbrich; R Kandolf; G M Cleator; A M van Loon
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.

Authors:  Qunying Mao; Yiping Wang; Jie Shao; Zhifang Ying; Fan Gao; Xin Yao; Changgui Li; Qiang Ye; Miao Xu; Rongcheng Li; Fengcai Zhu; Zhenglun Liang
Journal:  Hum Vaccin Immunother       Date:  2015-02-25       Impact factor: 3.452

7.  A new monoclonal antibody (Cox mAB 31A2) detects VP1 protein of coxsackievirus B3 with high sensitivity and specificity.

Authors:  Nicole Ettischer-Schmid; Andrea Normann; Martina Sauter; Lisa Kraft; Hubert Kalbacher; Reinhard Kandolf; Bertram Flehmig; Karin Klingel
Journal:  Virchows Arch       Date:  2016-08-27       Impact factor: 4.064

8.  Evaluation of the fidelity of immunolabelling obtained with clone 5D8/1, a monoclonal antibody directed against the enteroviral capsid protein, VP1, in human pancreas.

Authors:  Sarah J Richardson; Pia Leete; Shalinee Dhayal; Mark A Russell; Maarit Oikarinen; Jutta E Laiho; Emma Svedin; Katharina Lind; Therese Rosenling; Nora Chapman; Adrian J Bone; Alan K Foulis; Gun Frisk; Malin Flodstrom-Tullberg; Didier Hober; Heikki Hyoty; Noel G Morgan
Journal:  Diabetologia       Date:  2013-11-05       Impact factor: 10.122

9.  Maternal enterovirus infection as a risk factor for type 1 diabetes in the exposed offspring.

Authors:  Hanna Viskari; Mikael Knip; Sisko Tauriainen; Heini Huhtala; Riitta Veijola; Jorma Ilonen; Olli Simell; Heljä-Marja Surcel; Heikki Hyöty
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

Review 10.  Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges.

Authors:  Huitao Liu; Honglin Luo
Journal:  Viruses       Date:  2021-06-05       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.